
Quarterly report 2024-Q3
added 11-07-2024
Axonics Modulation Technologies Financial Ratios 2011-2026 | AXNX
Annual Financial Ratios Axonics Modulation Technologies
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-47.3 | -30.1 | -33.6 | -10.7 | -3.1 | - | - | - | - | - | - | - |
P/S |
10.3 | 13.4 | 16.6 | 61.6 | 140.5 | - | - | - | - | - | - | - |
EPS |
-1.3 | -1.9 | -1.5 | -2.8 | -4.6 | -7.0 | - | - | - | - | - | - |
EV (Enterprise Value) |
2.67 B | 2.26 B | 1.66 B | 717 M | 29.6 M | 71.4 M | 60.3 M | - | - | - | - | - |
EBITDA per Share |
-1.14 | -1.46 | -1.41 | -2.78 | -4.46 | - | - | - | - | - | - | - |
EV/EBITDA |
-36.0 | -34.9 | -8.8 | -0.7 | - | - | - | - | - | - | - | |
PEG |
- | -1.17 | -0.27 | 0.01 | - | - | - | - | - | - | - | |
P/B |
5.0 | 5.0 | 6.4 | 4.7 | 0.7 | - | - | - | - | - | - | - |
P/CF |
884.8 | -51.0 | -22.0 | -10.0 | -3.0 | - | - | - | - | - | - | - |
ROE % |
-10.47 | -16.60 | -19.11 | -43.68 | -22.67 | - | - | - | - | - | - | - |
ROA % |
-9.05 | -14.61 | -16.05 | -36.36 | -18.90 | - | - | - | - | - | - | - |
ROCE % |
-11.39 | -14.88 | -18.71 | -38.79 | -19.36 | - | - | - | - | - | - | - |
Current Ratio |
7.4 | 8.4 | 6.2 | 17.6 | 28.1 | - | - | - | - | - | - | - |
DSO |
49.2 | 47.9 | 42.8 | 208.1 | 220.4 | - | - | - | - | - | - | - |
DIO |
289.7 | 361.8 | 323.2 | 880.7 | 3765.9 | - | - | - | - | - | - | - |
DPO |
40.1 | 51.8 | 67.9 | 330.8 | 3522.9 | - | - | - | - | - | - | - |
Operating Cycle |
339.0 | 409.7 | 366.0 | 1088.8 | 3986.3 | - | - | - | - | - | - | - |
Cash Conversion Cycle |
298.8 | 357.9 | 298.1 | 758.0 | 463.4 | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Axonics Modulation Technologies
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | 0.14 | -0.38 | - | 0.08 | -0.15 | -0.19 | - | -0.34 | -0.47 | -0.5 | - | -0.38 | -0.59 | -0.57 | - | -0.24 | -0.54 | -0.43 | - | -0.89 | -0.68 | -0.47 | - | -2.67 | -3.07 | -2.36 | - | -1.67 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.08 | 0.12 | -0.31 | - | 0.03 | -0.2 | -0.24 | - | -0.16 | -0.42 | -0.45 | - | -0.22 | -0.32 | -0.52 | - | -0.19 | -0.51 | -0.43 | - | -0.86 | -0.67 | -0.48 | - | -2.43 | -2.91 | -2.25 | - | -1.51 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-1.34 | -0.69 | -2.98 | -2.18 | -5.14 | -8.74 | -12.42 | -12.75 | -16.27 | -16.83 | -16.92 | -15.32 | -18.51 | -18.18 | -20.08 | -15.16 | -28.82 | -39.30 | -42.83 | -31.25 | -36.53 | -28.14 | -23.77 | -15.93 | -9.12 | 2.97 | 9.01 | 6.81 | 6.81 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-1.75 | -2.88 | -4.93 | -2.26 | -3.70 | -6.27 | -9.45 | -11.20 | -14.27 | -10.46 | -14.91 | -12.58 | -15.26 | -14.86 | -16.20 | -12.73 | -24.11 | -32.80 | -35.69 | -26.01 | -30.42 | -23.44 | -19.80 | -13.27 | -28.65 | -39.62 | -34.59 | -15.37 | -15.37 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-3.54 | -2.71 | -5.29 | -4.61 | -7.59 | -10.46 | -13.35 | -12.95 | -16.32 | -16.71 | -14.99 | -13.09 | -16.14 | -15.83 | -19.40 | -14.92 | -28.61 | -39.24 | -43.02 | -31.66 | -36.92 | -28.50 | -23.98 | -15.83 | -8.92 | 3.26 | 9.28 | 6.91 | 6.91 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
7.1 | 7.2 | 8.1 | 8.7 | - | 13.4 | - | 7.4 | 7.6 | - | 8.5 | 8.4 | 7.9 | 9.2 | 3.9 | 6.2 | 6.2 | 6.2 | 6.2 | 6.0 | 6.0 | 6.0 | 6.0 | 6.0 | 6.0 | 6.0 | 6.0 | 11.6 | 11.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
47.1 | 42.9 | 53.8 | - | - | - | - | - | 24.0 | 18.1 | 53.2 | - | 50.9 | 46.9 | 52.8 | - | 47.3 | 109.6 | 45.4 | - | 549.2 | 483.2 | 351.9 | - | 193.8 | 3247.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
376.9 | 356.5 | 356.5 | - | - | - | - | - | 138.0 | 150.3 | 381.2 | - | 408.5 | 377.1 | 438.5 | - | 428.3 | 679.9 | 363.0 | - | 2260.9 | 1850.9 | 1609.5 | - | 3161.9 | 67032.2 | - | - | 595.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
67.8 | 63.0 | 70.5 | - | - | - | - | - | 23.8 | 25.2 | 54.2 | - | 57.9 | 55.6 | 72.2 | - | 72.4 | 114.9 | 76.3 | - | 849.3 | 695.2 | 775.8 | - | 2957.9 | 62707.0 | - | - | 624.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
424.0 | 399.4 | 410.3 | - | - | - | - | - | 161.9 | 168.4 | 434.4 | - | 459.4 | 424.0 | 491.3 | - | 475.6 | 789.5 | 408.3 | - | 2810.1 | 2334.1 | 1961.4 | - | 3355.8 | 70279.2 | - | - | 595.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
356.2 | 336.4 | 339.8 | - | - | - | - | - | 138.1 | 143.2 | 380.2 | - | 401.4 | 368.4 | 419.1 | - | 403.2 | 674.6 | 332.1 | - | 1960.9 | 1638.8 | 1185.6 | - | 397.9 | 7572.2 | - | - | -29.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Axonics Modulation Technologies, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Alphatec Holdings
ATEC
|
$ 11.75 | -3.29 % | $ 1.76 B | ||
|
BioSig Technologies
BSGM
|
- | 37.08 % | $ 85.7 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
- | - | $ 1.77 B | ||
|
Delcath Systems
DCTH
|
$ 8.98 | -1.32 % | $ 322 M | ||
|
Lianluo Smart Limited
LLIT
|
- | 24.59 % | $ 44.8 M | ||
|
Aziyo Biologics
AZYO
|
- | 1.37 % | $ 20.5 M | ||
|
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
- | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
- | -5.86 % | $ 30.6 M | ||
|
Second Sight Medical Products
EYES
|
- | -0.97 % | $ 54.4 M | ||
|
FONAR Corporation
FONR
|
$ 18.41 | 0.38 % | $ 121 M | ||
|
Conformis
CFMS
|
- | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | ||
|
Inogen
INGN
|
$ 6.32 | -2.02 % | $ 168 M | ||
|
Apollo Endosurgery
APEN
|
- | - | $ 475 M | ||
|
IRIDEX Corporation
IRIX
|
$ 1.35 | - | $ 21.8 M | ||
|
IRadimed Corporation
IRMD
|
$ 100.97 | 1.78 % | $ 1.28 B | ||
|
Avinger
AVGR
|
- | -20.74 % | $ 369 K | ||
|
CryoLife, Inc.
CRY
|
- | -4.14 % | $ 702 M | ||
|
LivaNova PLC
LIVN
|
$ 62.4 | -1.33 % | $ 3.4 B | ||
|
LENSAR
LNSR
|
$ 5.56 | -8.4 % | $ 64 M | ||
|
CHF Solutions, Inc.
CHFS
|
- | 1.15 % | $ 34.5 M | ||
|
AxoGen
AXGN
|
$ 32.61 | 2.71 % | $ 1.5 B | ||
|
CONMED Corporation
CNMD
|
$ 36.56 | -0.19 % | $ 1.13 B | ||
|
Medtronic PLC
MDT
|
$ 86.58 | -0.68 % | $ 111 B | ||
|
Soliton, Inc.
SOLY
|
- | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
- | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
- | 0.03 % | $ 1.58 B | ||
|
NanoVibronix
NAOV
|
- | - | $ 1.08 M | ||
|
Electromed
ELMD
|
$ 24.7 | 0.86 % | $ 209 M | ||
|
Misonix, Inc.
MSON
|
- | - | $ 462 M | ||
|
Neovasc
NVCN
|
- | - | $ 111 M | ||
|
InspireMD
NSPR
|
$ 1.79 | 3.47 % | $ 115 M | ||
|
Orthofix Medical
OFIX
|
$ 11.72 | -1.26 % | $ 464 M | ||
|
Intersect ENT, Inc.
XENT
|
- | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
$ 0.7 | 3.3 % | $ 38.1 M | ||
|
Aethlon Medical
AEMD
|
$ 2.16 | -6.09 % | $ 3.37 M | ||
|
Profound Medical Corp.
PROF
|
$ 5.15 | -4.63 % | $ 180 M | ||
|
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | ||
|
Penumbra
PEN
|
$ 334.17 | -0.41 % | $ 13 B | ||
|
AdaptHealth Corp.
AHCO
|
$ 11.48 | 10.7 % | $ 1.55 B | ||
|
Myomo
MYO
|
$ 0.7 | -1.83 % | $ 29.3 M | ||
|
Insulet Corporation
PODD
|
$ 225.5 | -0.7 % | $ 15.9 B | ||
|
Nano-X Imaging Ltd.
NNOX
|
$ 2.4 | -1.64 % | $ 141 M | ||
|
Invacare Corporation
IVC
|
- | - | $ 24.7 M | ||
|
EDAP TMS S.A.
EDAP
|
$ 3.91 | 4.83 % | $ 146 M | ||
|
Quanterix Corporation
QTRX
|
$ 3.82 | -3.05 % | $ 163 M | ||
|
OrthoPediatrics Corp.
KIDS
|
$ 15.91 | -3.4 % | $ 373 M | ||
|
Outset Medical
OM
|
$ 3.53 | -2.35 % | $ 53.7 K |